BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 31130488)

  • 1. Multiple Myeloma: Current Advances and Future Directions.
    Martin T; Huff CA
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):255-263. PubMed ID: 31130488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
    Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
    Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
    [No Abstract]   [Full Text] [Related]  

  • 3. The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.
    Feinberg D; Paul B; Kang Y
    Cell Immunol; 2019 Nov; 345():103964. PubMed ID: 31492448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
    Anderson LD
    Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
    Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor T cell therapies for multiple myeloma.
    Wu C; Zhang L; Brockman QR; Zhan F; Chen L
    J Hematol Oncol; 2019 Nov; 12(1):120. PubMed ID: 31752943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
    Su CT; Ye JC
    J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
    Huang H; Wu HW; Hu YX
    J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
    Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
    J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
    Lakshman A; Kumar SK
    Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune and Cell Therapy in Non-Hodgkin Lymphoma.
    Merryman RW; Houot R; Armand P; Jacobson C
    Cancer J; 2020; 26(3):269-277. PubMed ID: 32496460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma.
    Roschewski M; Phelan JD; Wilson WH
    Cancer J; 2020; 26(3):195-205. PubMed ID: 32496453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
    Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
    Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
    Ma T; Shi J; Liu H
    Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infusion of chimeric antigen receptor T cells against dual targets of CD19 and B-cell maturation antigen for the treatment of refractory multiple myeloma.
    Tang F; Lu Y; Ge Y; Shang J; Zhu X
    J Int Med Res; 2020 Jan; 48(1):300060519893496. PubMed ID: 31939323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
    Madduri D; Dhodapkar MV; Lonial S; Jagannath S; Cho HJ
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):537-544. PubMed ID: 31427259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
    Feng D; Sun J
    Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging agents and regimens for multiple myeloma.
    Yang Y; Li Y; Gu H; Dong M; Cai Z
    J Hematol Oncol; 2020 Nov; 13(1):150. PubMed ID: 33168044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
    Cohen AD
    Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor T-Cell Therapy.
    Ogba N; Arwood NM; Bartlett NL; Bloom M; Brown P; Brown C; Budde EL; Carlson R; Farnia S; Fry TJ; Garber M; Gardner RA; Gurschick L; Kropf P; Reitan JJ; Sauter C; Shah B; Shpall EJ; Rosen ST
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1092-1106. PubMed ID: 30181421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.